Zacks Touts AUNA's Strengths, but DeepValue Report Urges Caution on Mexico Recovery

What happened

Zacks Investment Research published an article advocating AUNA as a compelling ambulatory care stock over THC, citing strong Peru results, Mexico recovery signs, and improved cash flow. However, the latest DeepValue master report maintains a 'WAIT' rating, noting that Mexico's financials still show a 12% year-over-year revenue decline and 29% Adjusted EBITDA drop in 3Q25. While AUNA has reported sequential volume increases in Mexico and completed a debt refinancing to extend maturities, leverage remains elevated at ~3.6x Net Debt/EBITDA, and IT disruptions at Doctors Hospital continue to hinder utilization. The news article overlooks critical risks, such as the potential for equity dilution to fund AUNA's $500 million Mexico expansion plan, which could erode per-share value. Therefore, the optimistic narrative contrasts sharply with the operational and financial challenges documented in recent SEC filings, underscoring the need for skepticism.

Implication

The positive news from Zacks may provide a sentiment boost, but it doesn't alter the fundamental investment case, which hinges on Mexico's operational turnaround yet to be reflected in year-over-year financial metrics. AUNA's improved cash flow and Peru performance are encouraging, but they don't offset the core issue of high leverage and unresolved IT disruptions in Mexico, keeping the margin of safety limited. If AUNA announces equity financing for its Mexico plan while leverage stays above 3.6x, it could trigger a sell-off, aligning with the master report's bear scenario. The 'WAIT' rating is reinforced by the need for evidence, such as YoY revenue growth in Mexico and leverage improvement to below 3.3x by 2Q26, before considering an entry. Thus, prudent investors should await auditable data from upcoming filings, maintaining a risk-controlled stance until these checkpoints are met.

Thesis delta

The Zacks article does not shift the investment thesis, as no new operational or financial data has emerged to change the master report's cautious outlook. The core thesis remains that AUNA must demonstrate sustained YoY recovery in Mexico's revenue and EBITDA, coupled with deleveraging to below 3.3x, without dilutive equity financing. Until these conditions are fulfilled, the 'WAIT' rating with an attractive entry at $4.60 stands, and the positive spin in the news should be viewed as promotional rather than transformative.